147 related articles for article (PubMed ID: 16322899)
1. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.
Cleator S; Tsimelzon A; Ashworth A; Dowsett M; Dexter T; Powles T; Hilsenbeck S; Wong H; Osborne CK; O'Connell P; Chang JC
Breast Cancer Res Treat; 2006 Feb; 95(3):229-33. PubMed ID: 16322899
[TBL] [Abstract][Full Text] [Related]
2. Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Barros Filho MC; Katayama ML; Brentani H; Abreu AP; Barbosa EM; Oliveira CT; Góes JC; Brentani MM; Folgueira MA
Braz J Med Biol Res; 2010 Dec; 43(12):1225-31. PubMed ID: 21103787
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy.
Koike Folgueira MA; Brentani H; Carraro DM; De Camargo Barros Filho M; Hirata Katayama ML; Santana de Abreu AP; Mantovani Barbosa E; De Oliveira CT; Patrão DF; Mota LD; Netto MM; Caldeira JR; Brentani MM
Oncol Rep; 2009 Oct; 22(4):805-13. PubMed ID: 19724859
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P
Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009
[TBL] [Abstract][Full Text] [Related]
6. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.
Folgueira MA; Carraro DM; Brentani H; Patrão DF; Barbosa EM; Netto MM; Caldeira JR; Katayama ML; Soares FA; Oliveira CT; Reis LF; Kaiano JH; Camargo LP; Vêncio RZ; Snitcovsky IM; Makdissi FB; e Silva PJ; Góes JC; Brentani MM
Clin Cancer Res; 2005 Oct; 11(20):7434-43. PubMed ID: 16243817
[TBL] [Abstract][Full Text] [Related]
8. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
Hannemann J; Oosterkamp HM; Bosch CA; Velds A; Wessels LF; Loo C; Rutgers EJ; Rodenhuis S; van de Vijver MJ
J Clin Oncol; 2005 May; 23(15):3331-42. PubMed ID: 15908647
[TBL] [Abstract][Full Text] [Related]
9. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.
Jones LW; Fels DR; West M; Allen JD; Broadwater G; Barry WT; Wilke LG; Masko E; Douglas PS; Dash RC; Povsic TJ; Peppercorn J; Marcom PK; Blackwell KL; Kimmick G; Turkington TG; Dewhirst MW
Cancer Prev Res (Phila); 2013 Sep; 6(9):925-37. PubMed ID: 23842792
[TBL] [Abstract][Full Text] [Related]
10. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis.
Cleator SJ; Powles TJ; Dexter T; Fulford L; Mackay A; Smith IE; Valgeirsson H; Ashworth A; Dowsett M
Breast Cancer Res; 2006; 8(3):R32. PubMed ID: 16790077
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of biological pathways involved in chemotherapy response in breast cancer.
Tordai A; Wang J; Andre F; Liedtke C; Yan K; Sotiriou C; Hortobagyi GN; Symmans WF; Pusztai L
Breast Cancer Res; 2008; 10(2):R37. PubMed ID: 18445275
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
Sotiriou C; Powles TJ; Dowsett M; Jazaeri AA; Feldman AL; Assersohn L; Gadisetti C; Libutti SK; Liu ET
Breast Cancer Res; 2002; 4(3):R3. PubMed ID: 12052255
[TBL] [Abstract][Full Text] [Related]
13. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.
Liedtke C; Wang J; Tordai A; Symmans WF; Hortobagyi GN; Kiesel L; Hess K; Baggerly KA; Coombes KR; Pusztai L
Breast Cancer Res Treat; 2010 Jun; 121(2):301-9. PubMed ID: 19603265
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
[TBL] [Abstract][Full Text] [Related]
16. Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
Liedtke C; Hatzis C; Symmans WF; Desmedt C; Haibe-Kains B; Valero V; Kuerer H; Hortobagyi GN; Piccart-Gebhart M; Sotiriou C; Pusztai L
J Clin Oncol; 2009 Jul; 27(19):3185-91. PubMed ID: 19364972
[TBL] [Abstract][Full Text] [Related]
17. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease.
Modlich O; Prisack HB; Munnes M; Audretsch W; Bojar H
Clin Cancer Res; 2004 Oct; 10(19):6418-31. PubMed ID: 15475428
[TBL] [Abstract][Full Text] [Related]
18. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
Taylor KJ; Sims AH; Liang L; Faratian D; Muir M; Walker G; Kuske B; Dixon JM; Cameron DA; Harrison DJ; Langdon SP
Breast Cancer Res; 2010; 12(3):R39. PubMed ID: 20569502
[TBL] [Abstract][Full Text] [Related]
19. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
[TBL] [Abstract][Full Text] [Related]
20. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
